Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $120,494.01 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oruka Therapeutics Stock Up 4.7%

NASDAQ ORKA opened at $70.88 on Thursday. Oruka Therapeutics, Inc. has a 52 week low of $10.77 and a 52 week high of $91.00. The firm has a market capitalization of $4.27 billion, a P/E ratio of -36.54 and a beta of -0.26. The company has a 50-day moving average price of $64.29 and a 200-day moving average price of $44.86.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after buying an additional 420 shares during the period. AlphaCentric Advisors LLC increased its stake in shares of Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after buying an additional 788 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research report on Monday, April 27th. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. Stifel Nicolaus increased their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. UBS Group increased their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.